ZymeTx, Inc. - ZMTX new biotech company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ZymeTx, Inc. - ZMTX new biotech company

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: kimberley who wrote (32)	12/17/1997 12:40:00 AM
From: O. H. Rundell	Read Replies (2) of 88

Kim, From the website: Business Development During this year ZymeTx will undertake an aggressive program consisting of the following major elements: Launch through a marketing partner, the ViraSTAT line of Monoclonal Antibodies (MAbs) for the parainfluenza and influenza A/B. Complete development of lead compounds and reach agreement with a corporate partner to advance development of an influenza therapeutic. Develop to alpha trials a test for Herpes Simplex Virus and achieve the milestones listed for other disease as listed below. Disease Development Stage RSV Empirical Modeling Parainfluenza Substrate Synthesis CMV Enzyme Identification HSV Enzyme Identification To accomplish these objectives ZymeTx has relocated its operations to independent lab space while maintaining its close working and facilities sharing relationship with OMRF. ZymeTx will produce reagents in their own facilities and all other manufacturing will be contracted out. O. H.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next